{"url_path":"/sec/tcrx/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-276693-index.html","accession_number":"0001193125-26-276693","cik":"0001783328","ticker":"TCRX","issuer_name":"TScan Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1783328/0001193125-26-276693-index.html","primary_entity_key":"0001783328","primary_entity_name":"TScan Therapeutics, Inc."},"word_count":266,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn June 22, 2026, TScan Therapeutics, Inc. (the “Company”) issued a press release announcing positive initial data from Cohort C of the ongoing ALLOHA™ Phase 1 study evaluating TSC-101, generated with the commercial-ready manufacturing process, in patients with heme malignancies undergoing allogeneic hematopoietic cell transplantation. The Company also released an updated company presentation, which includes additional details of its heme malignancies clinical programs, including Cohort C data from the ALLOHA™ Phase 1 trial. Copies of the press release and the updated company presentation are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K. The updated company presentation will also be available in the investor relations section of the Company’s website at https://ir.tscan.com. Information contained on the Company’s website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, the Company’s website as part of this Current Report on Form 8-K.\n\nThe information under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibits 99.1 and 99.2."}